TSE:IMV

IMV Stock Forecast, Price & News

C$2.18

+0.08 (+3.81 %)

(As of 08/5/2021 12:12 PM ET)

Add

Compare

Today's Range

C$2.03

▼

C$2.18

50-Day Range

C$1.72

▼

C$2.97

52-Week Range

C$1.68

▼

C$6.92

Volume60,311 shs

Average Volume142,005 shs

Market CapitalizationC$178.94 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

30 days | 90 days | 365 days | Advanced Chart

Receive IMV News and Ratings via Email

Sign-up to receive the latest news and ratings for IMV and its competitors with MarketBeat's FREE daily newsletter.

About IMV

IMV Inc., a biopharmaceutical company, focuses on the development of cancer immunotherapies and vaccines against infectious diseases using its DPX delivery technology platform. The company's lead drug candidate includes maveropepimut-S (DPX-Survivac), a T cell therapy, which is in three Phase II clinical trials across 6 different cancer indications with and without Merck's Keytruda; and Phase II clinical trials for the treatment of ovarian cancer, and recurrent and refractory diffuse large B cell lymphoma. It is also developing DPX-COVID-19, a second-generation vaccine against severe acute respiratory syndrome coronavirus 2; and DPX-RSV, a vaccine candidate, which has completed Phase I clinical trials for the treatment of respiratory syncytial virus strain A, as well as DPX-SurMAGE for the treatment of bladder cancer and DPX-BRAF to treat melanoma patients. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.

IMV CEO steps down, search for a permanent replacement commences - Seeking Alpha
August 4, 2021 | seekingalpha.com

IMV Announces CEO Transition - Business Wire
August 4, 2021 | businesswire.com

IMV (IMV) to Release Quarterly Earnings on Wednesday
August 4, 2021 | americanbankingnews.com

IMV Inc. to Announce Second Quarter 2021 Results and Host a Conference Call and Webcast on August 11, 2021
August 2, 2021 | finance.yahoo.com

IMV to Participate in the BTIG Virtual Biotechnology Conference
July 29, 2021 | finance.yahoo.com

IMV (TSE:IMV) Stock Price Down 12.8%
July 27, 2021 | americanbankingnews.com

IMV (TSE:IMV) Trading Up 7.4%
July 23, 2021 | americanbankingnews.com

IMV (TSE:IMV) PT Lowered to C$2.50 at Raymond James
July 16, 2021 | americanbankingnews.com

IMV (TSE:IMV) Reaches New 1-Year Low at $1.70
July 16, 2021 | americanbankingnews.com

Clene, Inhibikase Therapeutics leads healthcare gainers; IMV, Tempest Therapeutics among major losers - Seeking Alpha
July 15, 2021 | seekingalpha.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange TSE
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolTSE:IMV
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.imvaccine.com
Phone+1-902-4921819
Employees77
Year FoundedN/A

Sales & Book Value

Annual SalesC$2,385.00
Price / Sales75,026.73
Cash FlowC$0.44 per share
Price / Cash Flow4.94
Book ValueC$0.39 per share
Price / Book5.55

Profitability

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares82,082,000
Market CapC$178.94 million
Next Earnings Date8/11/2021 (Confirmed)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

1.56 out of 5 stars

3.0 Analyst's Opinion

Consensus Rating
IMV has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 4 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of C$3.67, IMV has a forecasted upside of 72.1% from its current price of C$2.13.
Amount of Analyst Coverage
IMV has only been the subject of 3 research reports in the past 90 days.

4.8 Community Rank

Outperform Votes
IMV has received 84 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
IMV has received 33 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
IMV has received 71.79% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about IMV and other stocks. Vote “Outperform” if you believe IMV will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IMV will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
IMV does not currently pay a dividend.
Dividend Growth
IMV does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, IMV insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of IMV is -4.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of IMV is -4.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
IMV has a P/B Ratio of 5.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

IMV (TSE:IMV) Frequently Asked Questions

Is IMV a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IMV in the last year. There are currently 4 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" IMV stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IMV, but not buy additional shares or sell existing shares.
View analyst ratings for IMV or view top-rated stocks.

What stocks does MarketBeat like better than IMV?

Wall Street analysts have given IMV a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but IMV wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is IMV's next earnings date?

IMV is scheduled to release its next quarterly earnings announcement on Wednesday, August 11th 2021.
View our earnings forecast for IMV.

How were IMV's earnings last quarter?

IMV Inc. (TSE:IMV) announced its earnings results on Wednesday, May, 12th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.03. The business had revenue of $0.09 million for the quarter.
View IMV's earnings history.

How has IMV's stock been impacted by Coronavirus (COVID-19)?

IMV's stock was trading at C$3.39 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, IMV shares have decreased by 37.2% and is now trading at C$2.13.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for IMV?

4 analysts have issued 1 year price objectives for IMV's shares. Their forecasts range from C$2.50 to C$4.25. On average, they anticipate IMV's share price to reach C$3.67 in the next twelve months. This suggests a possible upside of 72.1% from the stock's current price.
View analysts' price targets for IMV or view top-rated stocks among Wall Street analysts.

Who are IMV's key executives?

IMV's management team includes the following people:

Mr. Frederic Ors M.B.A., B.Sc., M.A., CEO & Director (Age 47, Pay $771.72k)
Mr. Andrew Hall M.Sc., Chief Bus. Officer
Dr. Jeremy R. Graff, Chief Scientific Officer
Mr. Marc Jasmin CPA, CMA, Sr. Director of Investor Relations
Ms. Annie Tanguay B.Sc., Sr. VP of Quality & Compliance
Delphine Davan, Director of Communications
Ms. Linda Barabe M.B.A., VP of HR
Dr. Marianne Stanford, VP of R&D

Who are some of IMV's key competitors?

Some companies that are related to IMV include Biotest Aktiengesellschaft (BIO), Ergomed (ERGO), Silence Therapeutics (SLN), Brooklyn ImmunoTherapeutics (BTX), Inventiva (IVA), Pfenex (PFNX), Theratechnologies (TH), Nuvo Pharmaceuticals Inc. (NRI.TO) (NRI), Burcon NutraScience (BU), ProMetic Life Sciences (PLI), Synairgen (SNG), Horizon Discovery Group plc (HZD.L) (HZD), Aptose Biosciences (APS), BELLUS Health (BLU) and VIVO Cannabis (ABCN).
View all of IMV's competitors.

What other stocks do shareholders of IMV own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IMV investors own include Aurora Cannabis (ACB), 10094 (IRD.TO) (IRD), Village Farms International (VFF), Bombardier, Inc. Class B (BBD.B), (MJN.V) (MJN), Aphria (APHA), Enbridge (ENB), Sorrento Therapeutics (SRNE), Medical Facilities (DR) and ReNeuron Group (RENE).

What is IMV's stock symbol?

IMV trades on the Toronto Stock Exchange (TSX) under the ticker symbol "IMV."

How do I buy shares of IMV?

Shares of IMV and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is IMV's stock price today?

One share of IMV stock can currently be purchased for approximately C$2.13.

How much money does IMV make?

IMV has a market capitalization of C$174.83 million and generates C$2,385.00 in revenue each year.

How many employees does IMV have?

IMV employs 77 workers across the globe.

What is IMV's official website?

The official website for IMV is www.imvaccine.com.

Where are IMV's headquarters?

IMV is headquartered at 1344 Summer Street, Suite 412, HALIFAX, NS B3H 0A8, Canada.

How can I contact IMV?

IMV's mailing address is 1344 Summer Street, Suite 412, HALIFAX, NS B3H 0A8, Canada. The company can be reached via phone at +1-902-4921819.

This page was last updated on 8/5/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here